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Aims: Patients with diabetes mellitus (DM) are likely to develop asymptomatic myocardial
infarction as a complication. However, coronary artery lesions are difficult to assess in
internal medicine. This study aimed to develop a prediction formula for coronary artery
stenosis, as determined by coronary computed tomographic angiography (CCTA), by ana-
lyzing risk factors in patients with type 2 DM.
Methods: A prediction formula was developed based on a multivariate analysis of common
factors in patients withP50% coronary artery stenosis in a cohort of 327 patients with type
2 DM who underwent CCTA between 2007 and 2009, and cutoff values were calculated
(derivation study). The validity of the optimal cutoff value was confirmed in a separate
cohort of 317 patients with type 2 DM who underwent CCTA between 2010 and 2011 (vali-
dation study).
Results: In the derivation study, five predictive factors (presence/absence of hypertension,
estimated glomerular filtration rate, maximum intima-media thickness [max-IMT],
ankle-brachial index [ABI], and use/nonuse of diabetic medication) were used to develop
a prediction formula. In the validation study, positive predictive value (PPV) and negative
predictive value (NPV) of the cutoff value derived from the prediction formula were 53%
and 73%, respectively.
Conclusions: We developed a novel formula to predict coronary artery stenosis using five
predictive factors. This formula is useful for determining whether computed tomography
(CT) examination is necessary, even in clinical settings without CCTA equipment. Early
detection of coronary artery stenosis in patients with DM may also lead to better health
outcomes.
 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The incidence of type 2 diabetes mellitus (DM) is increasing
worldwide [1]. Approximately one-third of all patients with
type 2 DM live in Western Pacific countries, including Japan.
The prevalence of type 2 DM in this region was reported to
be 8.6% in 2013, and the number of patients with diabetic
complications is increasing. Therefore, appropriate treat-
ment of the disease and prevention of its complications
are vital. Diabetic complications are largely divided into
microvascular and macrovascular complications. Studies
such as the Kumamoto Study [2] and the United Kingdom
Prospective Diabetes Study 33 (UKPDS 33) [3] demonstrated
that intensive glycemic control prevents microvascular com-
plications. However, another study reported that silent
myocardial ischemia occurred in 22–39% of patients with
type 2 DM who already had an autonomic disorder as a com-
plication [4].
Currently classical risk factors for ischemic heart disease,
which is a major macro vascular complication of type 2 DM,
include smoking, dyslipidemia, hypertension, type 2 DM,
family history of heart disease, age, and sex [5–8]. Myocardial
infarction is the most serious macrovascular complication of
type 2 DM. Type 2 DM was shown to be a risk factor for
developing myocardial infarction in the Framingham Study
[9] and the UKPDS 35 [10]. However, the classical risk factors
alone do not sufficiently predict the occurrence of coronary
artery disease [11,12]; therefore, direct evaluation of the con-
dition of the coronary artery is important in type 2 DM
patients.
Multi-detector computed tomography (MDCT) is an impor-
tant instrument for detecting coronary artery stenosis. Recent
advances in MDCTallow non-invasive and rapid evaluation of
the coronary artery. With the development of this technology,
the accuracy of diagnosing coronary artery stenosis has
improved. A study investigating the accuracy of 64-slice
MDCT in assessing coronary artery stenosis reported that
the overall sensitivity, specificity, positive predictive value,
and negative predictive value for classifying stenosis were
94%, 97%, 87%, and 99%, respectively [13]. Coronary computed
tomography angiography (CCTA) is a specialized method for
evaluating the coronary artery in MDCT. However, CCTA is
not recommended for the screening of coronary artery dis-
ease in every patient with type 2 DM because it requires radi-
ation exposure and contrast agents.
The purpose of this study was to develop a model for pre-
dicting significant coronary artery stenosis in patients with
type 2 DM by examining the association between coronary
artery stenosis as assessed by CCTA and background risk fac-
tors. The cohort was divided into two groups; one cohort was
used for a derivation study and the second cohort was used
for a validation study. A prediction model was developed
using the data from the first cohort, and the validation was
performed using the data from the second cohort. In addition,
we compared the ability of the developed model to predict
coronary artery stenosis using subject data applied to the
UKPDS risk engine score, which estimated 10-year non-fatal
coronary heart disease risk.2. Material and methods
2.1. Subjects
All subjects were Japanese patients with type 2 DM who
underwent CCTA at Jinnouchi Hospital from June 2007 to
September 2011. We considered subjects eligible when they
fulfilled the following criteria: age 40 years or older at the time
of enrollment and diagnosis of type 2 DM by diabetologists
based on the Japan Diabetes Society’s criteria [14]. Based on
these initial eligibility criteria, study subjects needed to meet
at least one of these additional metrics for CCTA: (1) type 2
DM duration ofP10 years, (2) HbA1c of at leastP7%, (3) body
mass index (BMI) ofP25 kg/m2, and/or (4) history of smoking
and of having dyslipidemia. Study subjects underwent CCTA
regardless of symptoms or signs. We omitted patients from
the study withmissing data prior to study entry. Patients were
divided into derivation and validation cohorts (Fig. 1). The
derivation cohort comprised 327 patients who underwent
CCTA from June 2007 to December 2009, and the validation
cohort comprised 317 patients who underwent CCTA from
January 2010 to September 2011. Significant coronary artery
stenosis was defined as the presence of at least one stenotic
lesion with P50% coronary artery obstruction. The exclusion
criteria were (1) renal insufficiency, (2) contrast allergy, (3)
revascularization, (4) asthma, and (5) cardiac arrhythmias.
Patients with severe coronary calcification were excluded
due to the associated difficulty in evaluating the coronary
lumen. Severe coronary calcification was defined as the
lumen not being able to be described by short-axis view.
The study protocol was approved by Jinnouchi Hospital’s
committees on the ethics of human research. All subjects
enrolled in this study provided written informed consent.
2.2. Assessment of coronary artery disease by CCTA
CCTA was performed with a 64-slice MDCT scanner (Light-
Speed VCT, GE Medical Systems, Waukesha, Wisconsin,
USA) with 64  0.625-mm section collimation, a 350 or 400-
ms rotation time, a 120-kV tube voltage, and a pitch from
0.16 to 0.18 depending on the patient’s heart rate. The esti-
mated mean radiation dose was 15–18 mSv. A non-contrast
scan was initially performed to determine anatomical land-
marks for the contrast-enhanced study. Immediately there-
after, test bolus tracking with 10 mL of a non-ionic contrast
agent was applied to calculate the exact arrival time of the
contrast agent in the coronary arteries, with a region of inter-
est in the proximal part of the ascending aorta. Finally, a
contrast-enhanced scan with retrospective electrocardiogram
gating was performed after administration of the contrast
medium (220 mg I/kg body weight/10 s) during a single breath
hold. Image reconstruction was performed using image anal-
ysis software (CardIQ, GE Healthcare) on a dedicated com-
puter workstation (Advantage Workstation Ver. 4.2, GE
Healthcare). A standard kernel was used as the reconstruc-
tion filter. Depending on the patient’s heart rate, either a
half-scan or multi-segment reconstruction algorithm was
selected or the optimal cardiac phase with the fewest motion
Fig. 1 – Study flow for derivation and validation cohort.
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blockers and sublingual nitrates if necessary. Patients with
at least one stenotic lesion with P50% obstruction of the
coronary artery were considered to have significant coronary
artery stenosis. All CCTA images were evaluated by a radiolo-
gist and a radiological technologist. Atherosclerotic lesions
were classified visually as obstructive (P50% luminal narrow-
ing) or non-obstructive (<50% luminal narrowing).
2.2.1. Ankle-brachial index and pulse wave velocity
measurement
The ankle-brachial index (ABI) and brachial artery pulse wave
velocity (baPWV) were assessed using the automatic device
form PWV/ABI (BP-203PRE; Colin, Japan). Patients were placed
in the supine position for at least 5 min, and systolic blood
pressures of the brachial artery of each arm and the posterior
tibial arteries of each ankle were measured using a Doppler
probe. The highest blood pressure in the arms was used to
calculate the ABI. The ratio of ankle-to-arm systolic blood
pressure was calculated for each leg, and the lowest ratio
was recorded as the ABI for the patient. To measure baPWV,
pulse waves obtained from the brachial and tibial arteries
were recorded simultaneously, and transmission time, which
was defined as the time interval between the initial increase
in brachial and tibial waveforms, was determined. The trans-
mission distance from the arm to each ankle was calculated
based on the patient’s height. The baPWV value was automat-
ically computed as the transmission distance divided by the
transmission time. After obtaining bilateral baPWV values,
the higher value was used as the representative value for each
subject. Measurements obtained using form PWV/ABI have
been shown to have good reproducibility [15]. For our study,
we assessed intra-observer reproducibility in our institutes
by Bland–Altman analysis, which was performed in 28 con-
secutive subjects. The 95% CI of the mean difference of two
measurements included zero (CI: 0.011 to 0.001).2.2.2. Intima-media thickness
B-mode ultrasonography of the carotid artery was performed
using an ultrasound machine (SDU-1200, Shimazdu, Japan)
paired with a 7.5-MHz multi-frequency high-resolution linear
transducer. The near and far walls of the right and left com-
mon carotid arteries (CCAs) (at least 1.5 cm proximal to the
origin of the carotid bulb [CB], bifurcations at the CB) and
proximal internal carotid arteries (ICAs) were scanned. The
carotid intima-media thickness (IMT) was measured in the
posterior wall of the carotid artery as the distance between
the leading edge of the first and second echogenic lines.
The thickest points for the IMT (including plaque lesions) in
the CCA, ICA, and CB were recorded, and the highest value
among them was defined as the maximum IMT (max-IMT).
Reproducibility analysis of replicate measurements in 20 sub-
jects yielded absolute mean ± SD differences of 0.02 ± 0.01,
0.01 ± 0.01, 0.02 ± 0.01, and 0.01 ± 0.01 mm for mean-IMT-
CCA, max-IMT-CCA, max-IMT-Bulb, and max-IMT-ICA,
respectively.
2.3. Laboratory analysis
For analysis of serum concentrations of total cholesterol,
triglycerides (TG), creatine, high-density lipoprotein choles-
terol (HDL-C), low-density lipoprotein cholesterol (LDL-C),
and hemoglobin A1c (HbA1c), blood samples were collected
in the morning after an overnight fast while the patient was
in a seated position. Dyslipidemia was defined as LDL-C
P3.4 mmol/L, HDL-C <1.1 mmol/L, TG P1.7 mmol/L, or cur-
rent use of a lipid-lowering agent. Hypertension was defined
as systolic blood pressure (SBP) P140 mmHg, diastolic blood
pressure (DBP)P90 mmHg, or current use of an antihyperten-
sive agent. Smoking status was categorically defined on the
basis of self-reports. Estimated glomerular filtration rate
(eGFR) was determined by the modified Modification of
Diet and Renal Disease study formula (MDED) for Japanese
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(0.739 if female) [16]. The HbA1c level was converted from
the Japanese Diabetes Society value into the National
Glycohemoglobin Standardization Program (NGSP) equivalent
value [17].
2.4. Calculation of the UKPDS risk engine
We calculated the UKPDS risk engine score for individual sub-
jects and evaluated its predictive ability for coronary artery
stenosis by receiver-operating characteristic (ROC) curve anal-
yses as the UKPDS risk engine is an established type 2
diabetes-specific risk calculator for cardiovascular disease.
The UKPDS risk engine was downloaded from the UKPDS
website [18].
2.5. Statistical analysis
All values are reported as the means ± standard deviations,
median and interquartile range, or as the number of subjects
with percentages in parentheses. Between-group differences
of the average were compared using the unpaired t test for
parametric data, and the Mann–Whitney U test was used for
nonparametric data. The Spearman rank coefficient was used
to assess the correlation between coronary stenosis and
patient characteristics for parametric data, and the Pearson’sTable 1 – Baseline characteristics of the derivation population.
Coronary arter
(+)
n 198
Men 122 (61%)
Age (years) 71; 64–75
Type 2 diabetes duration (years) 16; 7–23
BMI (kg/m2) 23.9; 22.0–26.6
SBP (mmHg) 138.3 ± 16.4
DBP (mmHg) 78.3 ± 11.0
HbA1c (%) 7.4; 6.7-8.3
HbA1c (mmol/mol) 55.9; 48.7–65.3
LDL cholesterol (mmol/L) 3.0; 2.3–3.7
HDL cholesterol (mmol/L) 1.3; 1.1-1.7
Triglycerides (mmol/L) 3.0; 2.0–4.6
eGFR (mL/min/1.73 m2) 67; 54–77
ABI 1.12; 1.04-1.17
baPWV (cm/s) 1774; 1559–204
Hypertension 152 (76%)
Dyslipidemia 104 (53%)
Past or current smoker 89 (45%)
max-IMT (mm) 1.83; 1.35–2.6
Carotid plaque 178 (89%)
Diabetic medication 182 (92%)
Insulin treatment 73 (36%)
Oral anti-hyperglycemic agents 108 (55%)
Antihypertensive agents
Calcium blocker 83 (42%)
ACEI or ARB 83 (42%)
Lipid-lowerting agents
Statin 51 (25%)
UKPDS Score 34.1; 26.1–48.6
The value of SBP and DBP are the means ± standard deviations. Other va
diabetes patients with and without coronary stenosis by unpaired t test,correlation coefficient for nonparametric data. Multivariate
logistic regression analysis was used to detect independent
predictors of coronary stenosis. The ability of our regression
model to predict coronary stenosis was examined by ROC
curve analyses. We used the z test to calculate the statistical
significance of the different areas under the curve (AUC)
between our regression model and the UKPDS risk engine.
Statistical analysis was performed using SPSS Statistics
version 20.0 software (IBM Corporation, Armonk, New York,
USA), and C-statistical analyses were performed with EZR
(Saitama Medical Center, Jichi Medical University, Saitama,
Japan). For all tests, a p-value <0.05 was considered statisti-
cally significant.3. Results
Patient characteristics and medications are shown in Table 1.
The participants in the derivation study were 327 patients
with type 2 DM, consisting of 198 men and 129 women, with
a mean age of 68.3 ± 8.9 years, a mean duration of diabetes of
14.8 ± 9.7 years, and a mean HbA1c level of 7.5 ± 1.5% (57
± 13 mmol/mol). Overall, 61% of the derivation cohort had sig-
nificant coronary artery stenosis.
Clinical variables were compared between those with and
without coronary artery stenosis using the Mann–Whitney Uy stenosis p-Value
()
129
76 (58%) 0.63
69; 60–74 0.07
12; 6–18 0.04
23.4; 21.1–25.8 0.12
134.0 ± 16.0 0.02
78.0 ± 10.8 0.84
7.2; 6.5-8.2 0.06
53.9; 46.6–64.2 0.06
2.9; 2.3–3.5 0.56
1.4; 1.2–1.8 0.03
2.7; 2.0–3.9 0.17
73; 64–89 <0.01
1.15; 1.10–1.18 <0.01
4 1726; 1542–1930 0.13
79 (61%) <0.01
58 (45%) 0.18
54 (42%) 0.58
1.60; 1.15–2.07 <0.01
101 (78%) <0.01
106 (82%) 0.01
32 (24%) 0.02
72 (56%) 0.82
38 (29%) 0.02
39 (30%) 0.03
19 (14%) 0.02
28.9; 16.1–42.4 <0.01
lues are median (interquartile range) or n (%). P value compared with
Mann–Whitney U test.
Table 2 – Multivariate logistic regression analysis of coronary artery stenosis.
Variable b Coefficient OR (95% CI) p-Value
Hypertension 0.55 1.71 (1.02–2.94) 0.04
eGFR 0.02 0.98 (0.97–0.99) <0.01
ABI (per 0.1) 0.24 0.79 (0.62–0.99) 0.04
max-IMT 0.41 1.51 (1.09–2.08) 0.01
Diabetic treatment 0.84 2.32 (1.12–4.82) 0.02
OR, odds ratio; CI, confidence interval. Multivariate logistic regression analysis was performed with the presence of coronary artery stenosis as
a dependent variable, and diabetes duration, SBP, HDL-C, eGFR, ABI, hypertension, max-IMT, and use of diabetic medication and insulin
treatment as independent variables.
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tion, SBP, HDL-C, eGFR, ABI, hypertension, max-IMT, carotid
plaque occurrence, and use of diabetic medication and insu-
lin treatment (Table 1). We observed no significant difference
between men and women in the prevalence of coronary
artery disease in this cohort. Logistic regression analysis
showed that the significant factors associated with coronary
artery stenosis were hypertension, eGFR, max-IMT, ABI, and
use of diabetic medication (Table 2). The regression formula
was Y = 2.84 + 0.55  hypertension  0.02  eGFR + 0.41 
maxIMT  0.24  ABI + 0.84  diabetic medication. The opti-
mal cut-off point for the regression model was 0.17 (sensitiv-
ity, 67%; specificity, 63%). The validity of the cut-off point was
tested in a subgroup of 313 patients with type 2 DM (Table 3).Table 3 – Baseline characteristics of the validation population.
Coronary arter
(+)
n 113
Men 83 (73%)
Age (years) 67; 61–71
Diabetes duration (years) 16; 9–22
BMI (kg/m2) 24.1; 22.0–26.2
SBP (mmHg) 138.9 ± 14.2
DBP (mmHg) 78.3 ± 10.9
Hypertension 77 (68%)
HbA1c (%) 7.4; 6.8–8.2
HbA1c (mmol/mol) 55.9; 49.7–64.2
LDL cholesterol (mmol/L) 3.1; 2.6–3.6
HDL cholesterol (mmol/L) 1.3; 1.1–1.6
Triglycerides (mmol/L) 2.8; 2.1–4.4
eGFR (mL/min/1.73 m2) 75; 64–85
ABI 1.11; 1.03–1.17
baPWV (cm/s) 1705; 1518–193
Dyslipidemia 66 (58%)
Past or current smoking 59 (52%)
max-IMT (mm) 1.69; 1.20–2.26
Diabetic medication 102 (90%)
Insulin treatment 32 (28%)
Oral anti-hyperglycemic agents 70 (58%)
Antihypertensive agents
Calcium blocker 32 (28%)
ACEI or ARB 34 (30%)
Lipid-lowerting agents
Statin 14 (%)
UKPDS Score 27; 18–38
The value of SBP and DBP are the means ± standard deviations. Other val
diabetes patients with and without coronary stenosis by unpaired t test,The assessment revealed true-positive results in 70 patients
and true-negative results in 136 patients; additionally, there
were 68 false-positive and 43 false-negative cases. The values
for sensitivity, specificity, PPV, and NPV were 62%, 67%, 53%,
and 73%, respectively.
A comparison of the predictive ability of our model and the
UKPDS risk engine showed that the areas under the curve
(AUCs) in the ROC analysis were 0.70 (95% confidence interval
[CI], 0.64–0.76) for our model, 0.62 (95% CI, 0.56–0.69)
for the UKPDS risk engine, and 0.66 (95% CI, 0.59–0.72) for
the UKPDS risk engine + max-IMT. The AUC for our model
was significantly better than that for the UKPDS risk engine
(p = 0.03) and the UKPDS risk engine + max-IMT (p = 0.02)
(Fig. 2).y stenosis p-Value
()
204
134 (65%) 0.16
65; 58–72 0.29
11;5–21 0.01
24.0; 21.9–26.0 0.93
132.3 ± 15.6 <0.01
76.0 ± 10.3 0.11
99 (48%) <0.01
7.2; 6.6–8 0.06
53.8; 47.6–62.6 0.06
3.1; 2.6–3.6 0.61
1.4; 1.1–1.7 0.35
2.8; 2.0–4.3 0.57
80; 68–91 0.01
1.13; 1.08–1.18 <0.01
0 1584; 1391–1767 0.01
128 (62%) 0.45
94 (46%) 0.29
1.31; 1.02–1.72 <0.01
165 (81%) 0.03
48 (23%) 0.35
119 (58%) 0.53
48 (24%) 0.34
47 (23%) 0.21
16 (%) 0.55
20.5; 13-33 <0.01
ues are median (interquartile range) or n (%). P value compared with
Mann-Whitney U test.
Fig. 2 – Receiver-operating characteristic curve analysis to
predict coronary stenosis. Our model (hypertension
+ diabetic medication + ankle-brachial index + maximum
intima-media thickness [max-IMT] + estimated glomerular
filtration rate), the United Kingdom Prospective Diabetes
Study (UKPDS) risk engine, and the UKPDS risk engine
+ max-IMT.
96 d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 1 7 ( 2 0 1 6 ) 9 1 –9 94. Discussion
For the purposes of this research, we performed a multivari-
ate analysis to investigate the potential association between
coronary artery stenosis as assessed by CCTA in patients with
type 2 DM and background risk factors. We found that hyper-
tension, eGFR, max-IMT, ABI, and diabetic medication use
were independent predictive factors for coronary artery
stenosis. We further evaluated the validity of the cut-off point
for the prediction model and found that the PPV and NPV
were 53% and 73%, respectively. In addition, the accuracy of
our model for predicting coronary artery stenosis was better
than that of the UKPDS risk engine (AUC, 0.70 vs. 0.62,
p = 0.03). Silent myocardial ischemia was reported to occur
during stress testing in 22% of the patients with type 2 DM
who had no chest symptoms, suggesting a high prevalence
of coronary artery disease in patients with type 2 DM [4].
Patients with 50% or greater stenosis of the left main coronary
artery or those with 75% or greater stenosis of the other coro-
nary arteries on coronary CT are recommended to undergo
percutaneous coronary intervention [19]. Patients without
type 2 DM with 50% or greater stenosis had a 10-fold greater
risk of developing acute myocardial infarction than patients
with less than 50% stenosis [20]. Based on these findings,
we reasoned that predicting 50% or greater stenosis of the
coronary artery in patients with type 2 DM would be useful
for the early detection of high-risk patients and early phar-
macological intervention, which can prevent cardiovascular
events. In this study, therefore, we performed an analysis by
dividing patients into a stenosis group (those with 50% or
more obstruction) and a non-stenosis group (those with less
than 50% stenosis) based on CCTA results.Among the five predictive factors identified in the deriva-
tion study, hypertension has frequently been reported to be
a risk factor of ischemic heart disease and to be associated
with coronary artery stenosis [21]. Chronic kidney disease
(CKD) and decreased eGFR or positive urine protein are more
highly associated with coronary artery stenosis than normal
kidney function, and CKD severity is associated with coronary
artery stenosis severity [22]. Max-IMT, an index of arterial
sclerosis, is greater in patients with type 2 DM with coronary
artery stenosis [23]. In accordance with these findings, the
present study showed that these factors are independent pre-
dictors of coronary artery stenosis.
Interestingly, we found the prevalence of coronary artery
stenosis to be quite different between the derivation group
(60%) and the validation group (35%). We have determined
that such a difference might be based on the need to perform
CCTA clinically according to eligibility criteria. It might cause
this decrease of the prevalence in the latter period. Validation
of our model against the UKPDS risk engine clearly shows this
discrepancy, as there is a significant difference between the
derivation study (28 [10.4–39.5]) and validation study (23
[13.9–35.7]). In both cohorts, we found that hypertension,
eGFR, max-IMT, ABI, and diabetic medication use were inde-
pendent predictive factors for coronary artery stenosis.
Some researchers have reported that patients with coro-
nary artery stenosis, including individuals without type 2
DM, had decreased ABIs [24,25]. However, no previous studies
have reported the use of ABI as a risk factor in a predictive for-
mula for coronary artery stenosis in patients with type 2 DM.
Our study showed that ABI, which is determined by a nonin-
vasive and low-cost test and has clinical significance in
detecting coronary artery stenosis, is a predictor of coronary
artery stenosis in patients both with and without type 2 DM.
It is noteworthy that we found diabetic medication use to
be a predictor of coronary artery stenosis. A recent study
reported that patients with acute myocardial infarction and
type 2 DM had more advanced coronary artery disease than
those without type 2 DM [26]. The reason for this finding
may be that diabetic patients are prone to arteriosclerosis,
even in the early stages of the disease, and are likely to have
advanced coronary diseasewhen they start takingmedication
to help manage their diabetes. It is known that patients with
type 2 DM and obesity are prone to coronary artery stenosis,
even in the early stage of type 2 DM [27]. It is also known that
patients with a longer duration of type 2 DM have more
advanced coronary artery stenosis than those with a shorter
disease duration [28]. However, BMI and type 2 DM duration
were not significant predictive factors in our logistic regres-
sion analysis. A comparison of the two variables between
patients with and without diabetic medication use showed
significant differences; specifically, BMI was greater in those
taking diabetic medications (24.4 ± 4.2 kg/m2 vs. 23.0
± 3.1 kg/m2, p = 0.04), and the duration of diabetes was longer
in those taking diabetic medications (15.5 ± 9.5 years vs. 9.3
± 9.2 years, p < 0.01). We speculate that the differences in
these background characteristics may influence the associa-
tion between diabetic medication use and coronary artery
stenosis.
A recent study showed that an additional assessment of
HbA1c values provided little incremental benefit in predicting
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not a predictive factor for coronary artery stenosis, which
may be attributable to a limitation of the HbA1c measure-
ment at the time of CT examination. We considered that a
single HbA1c measurement might not have been sufficient
to evaluate the effect of type 2 DM on coronary artery
stenosis.
The results of the validation analysis showed a high NPV;
the PPV and NPV were 53% and 73%, respectively. We suggest
that patients should undergo CCTA only when the presence of
coronary artery stenosis cannot be ruled out by the regression
model, allowing efficient screening for coronary artery steno-
sis. Although the UKPDS risk engine is useful in predicting
coronary artery disease in patients with type 2 DM, our
regression model is more accurate in predicting coronary
artery stenosis. The regression model, involving indices of
arteriosclerosis (i.e., max-IMT and ABI), allows the prediction
of coronary artery stenosis based not only on lifestyle habits
and biochemistry but also on clinical parameters reflecting
vessel condition.
In addition, our prediction formula was consistent with
not only max-IMT (evaluation of macrovascular complica-
tions) but also ABI (evaluation of peripheral artery disease).
A key difference between our study and previous research
[30] is that our study predicted over 50% coronary stenosis
as well as whether patients required revascularization. It is
known that strict LDL treatment leads to the regression of
coronary artery plaque of [31]. Performing CCTA enables clin-
icians to evaluate coronary artery plaque at its presumably
earliest stages, and, if plaque is observed, the clinical team
can begin a strict medication regimen as needed. In turn, this
can lead to a slowing of the progression coronary stenosis and
associated cardiovascular events.
Recently, some controversies are discussed for clinical sig-
nificance of coronary revascularization therapy in the type 2
DM patients with severe but asymptomatic coronary artery
disease. In the BARI2D study, the results showed the intensive
and optimal medical therapy was useful for asymptomatic
coronary artery disease in type 2 DM patients to be adapted
for revascularization [32]. We have now recognized that the
limited utility of coronary angiography to identify severe
coronary artery disease in patients with type 2 DM. The inten-
sive and optimal medical therapies should be provided to all
type 2 DM patients. However, in the practical clinical situa-
tion, it is really difficult to achieve the optimal medical thera-
pies with multiple drug combination use, and lifestyle
intervention. We think that it must be important to recognize
the high-risk condition with the presence of coronary plaques
more than 50% stenosis for both patients and physicians in
the clinical situation. CCTA can give us the clear visual infor-
mation of coronary plaque burden and we can non-invasively
identify type 2 DM patients with moderate lesion stenosis
(>50%) in coronary arteries. We here demonstrated the useful
risk stratification strategy with non-invasive atherosclerotic
evaluation tests by IMT-measurement and ABI. Based on
these clinical information, we consider that the patients
and physicians can fully understand the atherosclerotic dis-
ease condition and the physician can extensively provide
the effective optimal medical therapies for type 2 DM
patients.It is clear that CT is essential for evaluating coronary artery
lesions. With advances in CT technology, delineation time
and radiation dose have been significantly reduced. However,
it is unrealistic to perform CCTA on every patient for the pur-
pose of screening for coronary artery disease. We believe that
the regression model developed in the present study is clini-
cally useful for coronary artery disease screening, particularly
for those patients with type 2 DM for whom CCTA is con-
traindicated or in situations in which patients are being trea-
ted in clinical settings without CCTA equipment.
4.1. Limitations
Our study has some limitations. One is that the calcification
score was not evaluated. A recent study reported that higher
calcification scores as measured by CCTA were associated
with higher mortality due to cardiovascular events in patients
with type 2 DM and that the addition of the calcification score
to the set of Framingham risk factors significantly improved
the prediction of cardiovascular death [33]. We did not include
the calcification score in the study design because our pri-
mary objective was to develop a model to guide decision-
making on whether CCTA should be performed. The other
limitation of our study is that this model was tested in a rel-
atively small number of Japanese patients. Further studies are
needed to generalize our findings to other races or ethnic
groups.
4.2. Conclusions
Our results showed that a regression model using five factors
that are feasibly obtained in clinical practice could predict the
presence of coronary artery stenosis in patients with type 2
DM. These factors are hypertension, eGFR, max-IMT, ABI
(both noninvasivemeasurements of arteriosclerosis), and dia-
betic medication (hypoglycemic drug or insulin) use. The
early detection of coronary artery stenosis enables the initia-
tion of earlier intervention of strictly medication for hyper-
tension and dyslipidemia, leading to an improved prognosis
in patients with type 2 DM at high risk for cardiovascular
events.
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